The authors reply

New England Journal of Medicine

Volumn 374, Issue 25, 2016, Pages 2497-2498

  Peyvandi, Flora ^a   Callewaert, Filip ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ABLYNX NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CAPLACIZUMAB; PLACEBO; FIBRINOLYTIC AGENT; NANOBODY; VON WILLEBRAND FACTOR;

ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA; DISEASE EXACERBATION; DRUG SAFETY; FOLLOW UP; GENERAL ASPECTS OF DISEASE; HUMAN; LETTER; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REFRACTORINESS; RELAPSE; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SINGLE-DOMAIN ANTIBODIES; VON WILLEBRAND FACTOR;

EID: 84975520856     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1603180     Document Type: Letter

References (3)

1. Benhamou Y, Boelle PY, Baudin B, et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura: experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 2015;13:293-302.
2. Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood 2015;125:3860-7.
3. Soucemarianadin M, Benhamou Y, Delmas Y, et al. Twicedaily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Eur J Haematol 2015 November 26 (Epub ahead of print).